Skip to main content
OpenTrials
Completed

NCT Number: NCT03387501

Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infertility, Female Urogenital Diseases

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Hospital Clinico San Carlos

Madrid, 28040, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women who signed informed consent.
  • Women who understand the Spanish language.
  • Women under 42 years

Exclusion criteria

  • Thrombopenia.
  • Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.
  • Ovarian tumors.
  • Benign uterine tumors require surgical treatment
  • Local acute inflammatory diseases
  • Patients with malignant tumors requiring chemotherapy.
  • Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.
  • Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)

Treatment and study plan

Plasma rich in growth factors (PRGF-Endoret)

Drug

Intrauterine administration of PRGF

Primary outcomes

  1. Percentage of women who achieve an endometrial thickness equal to or greater than 7 mm

    Time frame: 3 days after administration of PRGF

    Measurement of the endometrial thickness by ultrasonography.

Sponsors and collaborators

Lead sponsor

Sara Rafael Fernandez

Other

Registry information

Official study title

Efficacy and Safety of the Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium in Patients Undergoing Transfer of Cryo-preserved Embryos: Clinical Trial II.

Acronym: APTE

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Jan 2, 2018
Registry last updated
Sep 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.